Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2016

  • ID: 3674284
  • Drug Pipelines
  • 225 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Array BioPharma Inc.
  • Boehringer Ingelheim GmbH
  • CTI BioPharma Corp.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • MORE
Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2016

Summary

‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2016’, provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
- The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Array BioPharma Inc.
  • Boehringer Ingelheim GmbH
  • CTI BioPharma Corp.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Metastatic Adenocarcinoma of The Pancreas Overview

Therapeutics Development

Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview

Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis

Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies

Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes

Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies

Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes

Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development

AbbVie Inc.

Aduro BioTech, Inc.

Array BioPharma Inc.

Axcentua Pharmaceuticals AB

Berg LLC

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

CTI BioPharma Corp.

CytRx Corporation

Eleison Pharmaceuticals LLC

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Incyte Corporation

Merrimack Pharmaceuticals, Inc.

NewLink Genetics Corporation

Novartis AG

Oncolytics Biotech Inc.

Pfizer Inc.

Phoenix Biotechnology, Inc.

Plexxikon Inc.

Sanofi

Targovax AS

Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

aldoxorubicin hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AXP-10711 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BI-853520 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

binimetinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Cancer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ceritinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CRS-207 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

glufosfamide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GS-5745 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GSK-2256098 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INCB-52793 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

indoximod - Drug Profile

Product Description

Mechanism of Action

R&D Progress

irinotecan hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LGK-974 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MesoCART - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

napabucasin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

paclitaxel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PBI-05204 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pelareorep - Drug Profile

Product Description

Mechanism of Action

R&D Progress

plerixafor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PRI-724 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ribociclib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SGT-53 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sonidegib phosphate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TG-01 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tosedostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ubidecarenone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ulixertinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Metastatic Adenocarcinoma of The Pancreas - Recent Pipeline Updates

Metastatic Adenocarcinoma of The Pancreas - Dormant Projects

Metastatic Adenocarcinoma of The Pancreas - Discontinued Products

Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones

Featured News & Press Releases

Jan 25, 2016: Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium

Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission

Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2016

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Plexxikon Inc., H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Sanofi, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax AS, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Metastatic Adenocarcinoma of The Pancreas Therapeutics - Recent Pipeline Updates, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H1 2016

Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2016

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Aduro BioTech, Inc.
Array BioPharma Inc.
Axcentua Pharmaceuticals AB
Berg LLC
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
CTI BioPharma Corp.
CytRx Corporation
Eleison Pharmaceuticals LLC
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Incyte Corporation
Merrimack Pharmaceuticals, Inc.
NewLink Genetics Corporation
Novartis AG
Oncolytics Biotech Inc.
Pfizer Inc.
Phoenix Biotechnology, Inc.
Plexxikon Inc.
Sanofi
Targovax AS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll